Therapeutic strategies in multiple system atrophy
Identifieur interne :
000F46 ( PascalFrancis/Curation );
précédent :
000F45;
suivant :
000F47
Therapeutic strategies in multiple system atrophy
Auteurs : Gregor K. Wenning [
Autriche] ;
Felix Geser [
Autriche] ;
Werner Poewe [
Autriche]
Source :
-
Movement disorders [ 0885-3185 ] ; 2005.
RBID : Pascal:05-0457535
Descripteurs français
English descriptors
Abstract
This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with other warning features (red flags), and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in selected multiple regions of the brain and spinal cord. Because of the small number of randomized controlled trials, the management of MSA is largely based on empirical or open-label evidence. Parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, although more patients than previously recognized may experience an initial moderate-to-good dopaminergic response. There is no effective drug treatment for cerebellar ataxia. However, features of dysautonomia such as orthostatic hypotension, urinary retention or incontinence, constipation, and impotence, may often be relieved if recognized by the treating physician. Because no drug treatment consistently benefits patients with this disease in the long-term, palliative therapies are all the more important. Novel symptomatic and neuroprotective therapies are urgently required.
| pA |
| A01 | 01 | 1 | | @0 0885-3185 |
|---|
| A03 | | 1 | | @0 Mov. disord. |
|---|
| A05 | | | | @2 20 |
|---|
| A06 | | | | @3 SUP12 |
|---|
| A08 | 01 | 1 | ENG | @1 Therapeutic strategies in multiple system atrophy |
|---|
| A09 | 01 | 1 | ENG | @1 Atypical Parkinsonian Disorders |
|---|
| A11 | 01 | 1 | | @1 WENNING (Gregor K.) |
|---|
| A11 | 02 | 1 | | @1 GESER (Felix) |
|---|
| A11 | 03 | 1 | | @1 POEWE (Werner) |
|---|
| A12 | 01 | 1 | | @1 POEWE (Werner) @9 ed. |
|---|
| A12 | 02 | 1 | | @1 WENNING (Gregor K.) @9 ed. |
|---|
| A14 | 01 | | | @1 Innsbruck Medical University, Clinical Department of Neurology @3 AUT @Z 1 aut. @Z 2 aut. @Z 3 aut. |
|---|
| A15 | 01 | | | @1 Department of Neurology, Medical University Innsbruck @2 Innsbruck @3 AUT @Z 1 aut. @Z 2 aut. |
|---|
| A20 | | | | @2 S67-S76 |
|---|
| A21 | | | | @1 2005 |
|---|
| A23 | 01 | | | @0 ENG |
|---|
| A43 | 01 | | | @1 INIST @2 20953 @5 354000132714250110 |
|---|
| A44 | | | | @0 0000 @1 © 2005 INIST-CNRS. All rights reserved. |
|---|
| A45 | | | | @0 69 ref. |
|---|
| A47 | 01 | 1 | | @0 05-0457535 |
|---|
| A60 | | | | @1 P @2 C |
|---|
| A61 | | | | @0 A |
|---|
| A64 | 01 | 1 | | @0 Movement disorders |
|---|
| A66 | 01 | | | @0 USA |
|---|
| C01 | 01 | | ENG | @0 This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with other warning features (red flags), and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in selected multiple regions of the brain and spinal cord. Because of the small number of randomized controlled trials, the management of MSA is largely based on empirical or open-label evidence. Parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, although more patients than previously recognized may experience an initial moderate-to-good dopaminergic response. There is no effective drug treatment for cerebellar ataxia. However, features of dysautonomia such as orthostatic hypotension, urinary retention or incontinence, constipation, and impotence, may often be relieved if recognized by the treating physician. Because no drug treatment consistently benefits patients with this disease in the long-term, palliative therapies are all the more important. Novel symptomatic and neuroprotective therapies are urgently required. |
|---|
| C02 | 01 | X | | @0 002B17 |
|---|
| C02 | 02 | X | | @0 002B17F |
|---|
| C02 | 03 | X | | @0 002B17G |
|---|
| C03 | 01 | X | FRE | @0 Système nerveux pathologie @5 01 |
|---|
| C03 | 01 | X | ENG | @0 Nervous system diseases @5 01 |
|---|
| C03 | 01 | X | SPA | @0 Sistema nervioso patología @5 01 |
|---|
| C03 | 02 | X | FRE | @0 Atrophie multisystématisée @2 NM @5 02 |
|---|
| C03 | 02 | X | ENG | @0 Multiple system atrophy @2 NM @5 02 |
|---|
| C03 | 02 | X | SPA | @0 Atrofia multisistematizada @2 NM @5 02 |
|---|
| C03 | 03 | X | FRE | @0 Parkinsonisme @2 NM @5 03 |
|---|
| C03 | 03 | X | ENG | @0 Parkinsonism @2 NM @5 03 |
|---|
| C03 | 03 | X | SPA | @0 Parkinson síndrome @2 NM @5 03 |
|---|
| C03 | 04 | X | FRE | @0 Traitement @5 09 |
|---|
| C03 | 04 | X | ENG | @0 Treatment @5 09 |
|---|
| C03 | 04 | X | SPA | @0 Tratamiento @5 09 |
|---|
| C03 | 05 | X | FRE | @0 Stratégie @5 10 |
|---|
| C03 | 05 | X | ENG | @0 Strategy @5 10 |
|---|
| C03 | 05 | X | SPA | @0 Estrategia @5 10 |
|---|
| N21 | | | | @1 318 |
|---|
| N44 | 01 | | | @1 OTO |
|---|
| N82 | | | | @1 OTO |
|---|
|
|---|
| pR |
| A30 | 01 | 1 | ENG | @1 Atypical Parkinsonian Disorders - From Protein Dysfunction to Therapeutic Intervention. International Meeting @3 Innsbruck AUT @4 2003-02-19 |
|---|
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D75
Links to Exploration step
Pascal:05-0457535
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Therapeutic strategies in multiple system atrophy</title>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Innsbruck Medical University, Clinical Department of Neurology</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Innsbruck Medical University, Clinical Department of Neurology</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Innsbruck Medical University, Clinical Department of Neurology</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0457535</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0457535 INIST</idno>
<idno type="RBID">Pascal:05-0457535</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001D75</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F46</idno>
</publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Therapeutic strategies in multiple system atrophy</title>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Innsbruck Medical University, Clinical Department of Neurology</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Geser, Felix" sort="Geser, Felix" uniqKey="Geser F" first="Felix" last="Geser">Felix Geser</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Innsbruck Medical University, Clinical Department of Neurology</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Innsbruck Medical University, Clinical Department of Neurology</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14><country>Autriche</country>
</affiliation><series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint><seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Multiple system atrophy</term>
<term>Nervous system diseases</term>
<term>Parkinsonism</term>
<term>Strategy</term>
<term>Treatment</term>
</keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Atrophie multisystématisée</term>
<term>Parkinsonisme</term>
<term>Traitement</term>
<term>Stratégie</term>
</keywords><front><div type="abstract" xml:lang="en">This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with other warning features (red flags), and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in selected multiple regions of the brain and spinal cord. Because of the small number of randomized controlled trials, the management of MSA is largely based on empirical or open-label evidence. Parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, although more patients than previously recognized may experience an initial moderate-to-good dopaminergic response. There is no effective drug treatment for cerebellar ataxia. However, features of dysautonomia such as orthostatic hypotension, urinary retention or incontinence, constipation, and impotence, may often be relieved if recognized by the treating physician. Because no drug treatment consistently benefits patients with this disease in the long-term, palliative therapies are all the more important. Novel symptomatic and neuroprotective therapies are urgently required.</div>
</front><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01><fA03 i2="1"><s0>Mov. disord.</s0>
</fA03><fA06><s3>SUP12</s3>
</fA06><fA08 i1="01" i2="1" l="ENG"><s1>Therapeutic strategies in multiple system atrophy</s1>
</fA08><fA09 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders</s1>
</fA09><fA11 i1="01" i2="1"><s1>WENNING (Gregor K.)</s1>
</fA11><fA11 i1="02" i2="1"><s1>GESER (Felix)</s1>
</fA11><fA11 i1="03" i2="1"><s1>POEWE (Werner)</s1>
</fA11><fA12 i1="01" i2="1"><s1>POEWE (Werner)</s1>
<s9>ed.</s9>
</fA12><fA12 i1="02" i2="1"><s1>WENNING (Gregor K.)</s1>
<s9>ed.</s9>
</fA12><fA14 i1="01"><s1>Innsbruck Medical University, Clinical Department of Neurology</s1>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14><fA15 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA15><fA20><s2>S67-S76</s2>
</fA20><fA21><s1>2005</s1>
</fA21><fA23 i1="01"><s0>ENG</s0>
</fA23><fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000132714250110</s5>
</fA43><fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44><fA45><s0>69 ref.</s0>
</fA45><fA47 i1="01" i2="1"><s0>05-0457535</s0>
</fA47><fA60><s1>P</s1>
<s2>C</s2>
</fA60><fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64><fA66 i1="01"><s0>USA</s0>
</fA66><fC01 i1="01" l="ENG"><s0>This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with other warning features (red flags), and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in selected multiple regions of the brain and spinal cord. Because of the small number of randomized controlled trials, the management of MSA is largely based on empirical or open-label evidence. Parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, although more patients than previously recognized may experience an initial moderate-to-good dopaminergic response. There is no effective drug treatment for cerebellar ataxia. However, features of dysautonomia such as orthostatic hypotension, urinary retention or incontinence, constipation, and impotence, may often be relieved if recognized by the treating physician. Because no drug treatment consistently benefits patients with this disease in the long-term, palliative therapies are all the more important. Novel symptomatic and neuroprotective therapies are urgently required.</s0>
</fC01><fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02><fC02 i1="02" i2="X"><s0>002B17F</s0>
</fC02><fC02 i1="03" i2="X"><s0>002B17G</s0>
</fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03><fC03 i1="02" i2="X" l="FRE"><s0>Atrophie multisystématisée</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="ENG"><s0>Multiple system atrophy</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03><fC03 i1="02" i2="X" l="SPA"><s0>Atrofia multisistematizada</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03><fC03 i1="03" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03><fC03 i1="03" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03><fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0>
<s5>09</s5>
</fC03><fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0>
<s5>09</s5>
</fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>09</s5>
</fC03><fC03 i1="05" i2="X" l="FRE"><s0>Stratégie</s0>
<s5>10</s5>
</fC03><fC03 i1="05" i2="X" l="ENG"><s0>Strategy</s0>
<s5>10</s5>
</fC03><fC03 i1="05" i2="X" l="SPA"><s0>Estrategia</s0>
<s5>10</s5>
</fC03><fN21><s1>318</s1>
</fN21><fN44 i1="01"><s1>OTO</s1>
</fN44><fN82><s1>OTO</s1>
</fN82><pR><fA30 i1="01" i2="1" l="ENG"><s1>Atypical Parkinsonian Disorders - From Protein Dysfunction to Therapeutic Intervention. International Meeting</s1>
<s3>Innsbruck AUT</s3>
<s4>2003-02-19</s4>
</fA30>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000F46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:05-0457535
|texte= Therapeutic strategies in multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 |  |
